Epizyme presented results of a pre-clinical study of its EZH2 inhibitor EPZ-6438 in models of synovial sarcoma at the CTOS meeting in 2014:
http://www.epizyme.com/wp-content/uploads/2014/10/E7438-CTOS-Poster...
More information here:
http://www.epizyme.com/wp-content/uploads/2014/10/CTOS-SS-Press-Rel...
There is a clinical trial in France and Australia recruiting patients: